Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 3, Issue 4, Pages 386-390Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1471-4892(03)00083-3
Keywords
-
Categories
Ask authors/readers for more resources
Targeted delivery of cytotoxic agents to tumours is believed to improve both their anti-tumour efficacy and their safety. Antibodies specific for tumour-associated antigens have been used to deliver cytotoxic agents to tumour cells. Calicheamicin is a potent cytotoxic agent that causes double-strand DNA breaks, resulting in cell death. When conjugated to monoclonal antibodies specific for tumour-associated antigens, calicheamicin exerts strong antigen-specific anti-tumour effects against human tumour xenografts in preclinical models. Anti body-targeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg(R)), is a clinically validated therapeutic strategy for the treatment of human cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available